Moderna (MRNA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Moderna (MRNA)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

47.44

-4.15 (8.04%)

as of Jun 5, 2026, 8:00:00 pm Market Open.

142 watching

Investor Insights

Jun 5, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Moderna (MRNA-Q) has shown a significant turnaround in performance, with a remarkable increase of 72% in Q1, bolstered by the resolution of some lawsuits that had previously weighed on the company. The FDA approval of its new flu vaccine is another positive development, especially with impending changes in regulatory leadership that may favor its future endeavors. However, while the stock saw a nearly 50% rally last month, there are concerns about its long-term profitability and reliance on returning to revenue growth by 2026. The biotech market's binary nature adds uncertainty, leading some experts to question whether Moderna can effectively leverage its technology in adjacent markets. Overall, the sentiment around Moderna is mixed, with potential for growth but also significant risks involved.

Consensus

Mixed

Valuation

Fair Value

Similar

Pfizer, PFE

BUY

It's down 5% today, but he has conviction for it. Less than 10x earnings this year and next, and boasts one of the best drug pipelines in the industry.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Apr 07/21, Up 125%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with MNRA has triggered its stop at $300. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment return of 78%.

SELL

He owned it and sold it way too early. All the good news is in this stock for the next two years. It was well ahead of the fundamentals. Watch for another opportunity with them. It's fully valued right now.

BUY

It had a huge run. When the pandemic ends, the prices on their shots will leap from $25 to $150-200 which is normal for booster shots. Think of the profitability and their pipeline of 34 drugs.

DON'T BUY

In the news for their vaccine. It's pretty much all their business right now. Total revenue was $60M, but their market cap is $170B. The question is, are their legs with the vaccine franchise. They have lots of drugs in their pipeline, but there is a lot of risk.

Premium content

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

They have done well with their Covid vaccine. Their targeted cancer vaccine is expected to generate even more revenues. Can do a lot with its formulation. Has many drugs in the pipeline. Social media mentions are up 192%.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Apr 08/21, Up 213.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA is progressing well. We recommend trailing up the stop (from $175) to $300. Along with the previous recommendation to cover half the position, this would all but guarantee a net investment return of 78% if triggered.

BUY

Their targeted cancer vaccines will dwarf their revenues from even Covid. These are really smart guys and they're making tons of money.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Apr 08/21, Up 76.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRN is progressing well. We now recommend trailing up the stop (from $134) to $175. If triggered, this would all but guarantee a net investment return of 31%, when considering our previous recommendation to cover 50% of the holding.

BUY

He prefers it to Novavax, despite Novavax's good run today, because Moderna can do a lot more with its formulation.

BUY

Novavax Novavax is not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Apr 08/21, Up 31.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA has achieved our $175 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop to $134, just above the original recommended entry level. This would all but guarantee a minimum investment return exceeding 15%.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly MRNA is now a well known name in the production of COVID-19 vaccine and is only one of three that have received approval in the US. Purchase agreements amounted to $18 billion, allowing cash flow reserves of the company to balloon. The company is now working on a single-dose product that does not require extreme refrigeration. The pullback in the share price, and a forward PE of 9x earnings, offers a good entry level here. We would buy this with a stop loss at $90, looking to achieve $175 -- upside potential of 29%. Yield 0% (Analysts’ price target is $174.25)

BUY

A year ago, Moderna was a speculative, untested biotech stock. Now, they've had great success with their Covid vaccine. Their RN technology extends beyond this virus, so the stock has a runway with possible non-Covid blockbusters ahead.

DON'T BUY

The stock is being priced and valued on emotion, it is hard to value. The average target is $148 a year out. However, there has been downgrades with price targets now lower than where it is at right now. This year, they will make a lot of money because of covid, but after, it is questionable. It will be volatile.

Showing 46 to 60 of 64 entries

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Moderna (MRNA)

Moderna(MRNA)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Moderna(MRNA)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Moderna(MRNA)

Moderna(MRNA)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Moderna(MRNA)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna (MRNA) Frequently Asked Questions

What is Moderna stock symbol?

Is Moderna a buy or a sell?

Is Moderna a good investment or a top pick?

Why is Moderna stock dropping?

Is Moderna worth watching?

What is Moderna stock price?

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Brian Madden

The Panic-Proof Portfolio (Stockchase Research)

Darren Sissons

The Weekly Buzzing Stocks by Billy Kawasaki

Joe Terranova